Drug intelligence / Profile preview

cetuximab + docetaxel

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of cetuximab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR), and docetaxel, a taxane-based chemotherapy agent. This combination works through multiple mechanisms including EGFR signaling inhibition, disruption of microtubule function, and potential immunostimulatory effects. It has been studied primarily in squamous cell carcinoma of the head and neck (SCCHN) and non-small-cell lung cancer (NSCLC).

Brand names: ErbituxTaxotere
Other names: TXTdocetaxel-University of Miami-head and neck squamous cell carcinoma

Targets

TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on cetuximab + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + docetaxel.

Explore the full profile